Works by Zelenetz, Andrew D.

Results: 75
    1
    2
    3

    Prospective Study of 3'-Deoxy-3'-<sup>18</sup>F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.

    Published in:
    Journal of Nuclear Medicine, 2016, v. 57, n. 5, p. 728, doi. 10.2967/jnumed.115.166769
    By:
    • Schöder, Heiko;
    • Zelenetz, Andrew D.;
    • Hamlin, Paul;
    • Gavane, Somali;
    • Horwitz, Steven;
    • Matasar, Matthew;
    • Moskowitz, Alison;
    • Noy, Ariela;
    • Palomba, Lia;
    • Portlock, Carol;
    • Straus, David;
    • Grewal, Ravinder;
    • Migliacci, Jocelyn C.;
    • Larson, Steven M.;
    • Moskowitz, Craig H.
    Publication type:
    Article
    4
    5
    6
    7

    Romidepsin and lenalidomide‐based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts.

    Published in:
    American Journal of Hematology, 2021, v. 96, n. 10, p. 1211, doi. 10.1002/ajh.26288
    By:
    • Mehta‐Shah, Neha;
    • Lunning, Matthew A.;
    • Moskowitz, Alison J.;
    • Boruchov, Adam M.;
    • Ruan, Jia;
    • Lynch, Peggy;
    • Hamlin, Paul A.;
    • Leonard, John;
    • Matasar, Matthew J.;
    • Myskowski, Patricia L.;
    • Marzouk, Evan;
    • Nair, Sumithra;
    • Sholklapper, Tamir;
    • Minnal, Veena;
    • Palomba, Maria L.;
    • Vredenburgh, James;
    • Kumar, Anita;
    • Noy, Ariela;
    • Straus, David J.;
    • Zelenetz, Andrew D.
    Publication type:
    Article
    8

    Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma.

    Published in:
    American Journal of Hematology, 2020, v. 95, n. 5, p. 510, doi. 10.1002/ajh.25757
    By:
    • Timmerman, John;
    • Herbaux, Charles;
    • Ribrag, Vincent;
    • Zelenetz, Andrew D.;
    • Houot, Roch;
    • Neelapu, Sattva S.;
    • Logan, Theodore;
    • Lossos, Izidore S.;
    • Urba, Walter;
    • Salles, Gilles;
    • Ramchandren, Radhakrishnan;
    • Jacobson, Caron;
    • Godwin, John;
    • Carpio, Cecilia;
    • Lathers, Deanne;
    • Liu, Yali;
    • Neely, Jaclyn;
    • Suryawanshi, Satyendra;
    • Koguchi, Yoshinobu;
    • Levy, Ronald
    Publication type:
    Article
    9
    10

    Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma.

    Published in:
    Blood Cancer Journal, 2022, v. 12, n. 2, p. 1, doi. 10.1038/s41408-022-00620-w
    By:
    • Sha, Fushen;
    • Okwali, Michelle;
    • Alperovich, Anna;
    • Caron, Philip C.;
    • Falchi, Lorenzo;
    • Hamilton, Audrey;
    • Hamlin, Paul A.;
    • Horwitz, Steven M.;
    • Joffe, Erel;
    • Khan, Niloufer;
    • Kumar, Anita;
    • Matasar, Matthew J.;
    • Moskowitz, Alison J.;
    • Noy, Ariela;
    • Owens, Colette;
    • Palomba, Lia M.;
    • Rodriguez-Rivera, Ildefonso;
    • Straus, David;
    • von Keudell, Gottfried;
    • Zelenetz, Andrew D.
    Publication type:
    Article
    11

    Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse.

    Published in:
    Blood Cancer Journal, 2021, v. 11, n. 6, p. 1, doi. 10.1038/s41408-021-00506-3
    By:
    • Bobillo, Sabela;
    • Joffe, Erel;
    • Sermer, David;
    • Mondello, Patrizia;
    • Ghione, Paola;
    • Caron, Philip C.;
    • Hamilton, Audrey;
    • Hamlin, Paul A.;
    • Horwitz, Steven M.;
    • Kumar, Anita;
    • Matasar, Matthew J.;
    • Batlevi, Connie L.;
    • Moskowitz, Alison;
    • Noy, Ariela;
    • Owens, Collette N.;
    • Palomba, M. Lia;
    • Straus, David;
    • von Keudell, Gottfried;
    • Dogan, Ahmet;
    • Zelenetz, Andrew D.
    Publication type:
    Article
    12

    Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse.

    Published in:
    Blood Cancer Journal, 2019, v. 9, n. 6, p. N.PAG, doi. 10.1038/s41408-019-0209-5
    By:
    • Kumar, Anita;
    • Sha, Fushen;
    • Toure, Ahmed;
    • Dogan, Ahmet;
    • Ni, Andy;
    • Batlevi, Connie L.;
    • Palomba, Maria Lia M.;
    • Portlock, Carol;
    • Straus, David J.;
    • Noy, Ariela;
    • Horwitz, Steven M.;
    • Moskowitz, Alison;
    • Hamlin, Paul;
    • Moskowitz, Craig H.;
    • Matasar, Matthew J.;
    • Zelenetz, Andrew D.;
    • Younes, Anas
    Publication type:
    Article
    13
    14
    15
    16
    17
    18

    The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study.

    Published in:
    HemaSphere, 2024, v. 8, n. 8, p. 1, doi. 10.1002/hem3.138
    By:
    • Zelenetz, Andrew D.;
    • Jurczak, Wojciech;
    • Ribrag, Vincent;
    • Linton, Kim;
    • Collins, Graham P.;
    • Jiménez, Javier L.;
    • Bishton, Mark;
    • Dholaria, Bhagirathbhai;
    • Mengarelli, Andrea;
    • Phillips, Tycel J.;
    • Sungala, Nagendraprasad;
    • Musuraca, Gerardo;
    • Sheehy, Oonagh;
    • Van Den Neste, Eric;
    • Odera, Mitsuhiko;
    • Miao, Lu;
    • Gold, Daniel P.;
    • Ghalie, Richard G.;
    • Zinzani, Pier L.
    Publication type:
    Article
    19

    P1087: PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH >3 YEARS FOLLOW-UP FROM START OF ENROLLMENT.

    Published in:
    2023
    By:
    • Jurczak, Wojciech;
    • Luigi Zinzani, Pier;
    • Eyre, Toby A.;
    • Cheah, Chan Y.;
    • Ujjani, Chaitra S.;
    • Izutsu, Koji;
    • MA, Shuo;
    • Flinn, Ian;
    • Alencar, Alvaro J.;
    • Lewis, David;
    • Patel, Krish;
    • Maddocks, Kami;
    • Wang, Yucai;
    • Munir, Talha;
    • Zelenetz, Andrew D.;
    • Balbas, Minna;
    • Tsai, Donald E.;
    • Wang, Chunxiao;
    • Wang, Michael L.;
    • Shah, Nirav N.
    Publication type:
    Abstract
    20
    21
    22
    23
    24
    25

    Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience.

    Published in:
    Leukemia & Lymphoma, 2022, v. 63, n. 4, p. 876, doi. 10.1080/10428194.2021.2002318
    By:
    • Pak, Terry K.;
    • Dixon, Brianne N.;
    • Buege, Michael J.;
    • Dao, Phuong H.;
    • Leary, Megan H.;
    • Jarrett, Joy C.;
    • Duggan, Tara A.;
    • Caron, Philip;
    • Falchi, Lorenzo;
    • Hamlin, Paul;
    • Hamilton, Audrey;
    • Matasar, Matthew J.;
    • Moskowitz, Alison;
    • Noy, Ariela;
    • Owens, Colette N.;
    • Von Keudell, Gottfried;
    • Younes, Anas;
    • Zelenetz, Andrew D.;
    • Kumar, Anita
    Publication type:
    Article
    26
    27
    28
    29

    Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.

    Published in:
    Leukemia & Lymphoma, 2019, v. 60, n. 4, p. 894, doi. 10.1080/10428194.2018.1515940
    By:
    • Sharman, Jeff P.;
    • Forero-Torres, Andres;
    • Costa, Luciano J.;
    • Flinn, Ian W.;
    • Inhorn, Lowell;
    • Kelly, Kevin;
    • Bessudo, Alberto;
    • Fayad, Luis E.;
    • Kaminski, Mark S.;
    • Evens, Andrew M.;
    • Flowers, Christopher R.;
    • Sahin, Deniz;
    • Mundt, Kirsten E.;
    • Sandmann, Thomas;
    • Fingerle-Rowson, Günter;
    • Vignal, Charlotte;
    • Mobasher, Mehrdad;
    • Zelenetz, Andrew D.
    Publication type:
    Article
    30
    31

    Management of adverse events associated with idelalisib treatment: expert panel opinion.

    Published in:
    Leukemia & Lymphoma, 2015, v. 56, n. 10, p. 2779, doi. 10.3109/10428194.2015.1022770
    By:
    • Coutré, Steven E.;
    • Barrientos, Jacqueline C.;
    • Brown, Jennifer R.;
    • de Vos, Sven;
    • Furman, Richard R.;
    • Keating, Michael J.;
    • Li, Daniel;
    • O'Brien, Susan M.;
    • Pagel, John M.;
    • Poleski, Martin H.;
    • Sharman, Jeff P.;
    • Yao, Nai-Shun;
    • Zelenetz, Andrew D.
    Publication type:
    Article
    32

    Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database

    Published in:
    Leukemia & Lymphoma, 2013, v. 54, n. 10, p. 2155, doi. 10.3109/10428194.2013.770151
    By:
    • Abou-Nassar, Karim E.;
    • Vanderplas, Ann;
    • Friedberg, Jonathan W.;
    • Abel, Gregory A.;
    • Niland, Joyce;
    • Rodriguez, Maria A.;
    • Czuczman, Myron S.;
    • Millenson, Michael;
    • Crosby, Allison;
    • Gordon, Leo I.;
    • Zelenetz, Andrew D.;
    • Kaminski, Mark;
    • Lacasce, Ann S.
    Publication type:
    Article
    33
    34

    A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era.

    Published in:
    British Journal of Haematology, 2014, v. 165, n. 3, p. 358, doi. 10.1111/bjh.12753
    By:
    • Hosein, Peter J.;
    • Maragulia, Jocelyn C.;
    • Salzberg, Matthew P.;
    • Press, Oliver W.;
    • Habermann, Thomas M.;
    • Vose, Julie M.;
    • Bast, Martin;
    • Advani, Ranjana H.;
    • Tibshirani, Robert;
    • Evens, Andrew M.;
    • Islam, Nahida;
    • Leonard, John P.;
    • Martin, Peter;
    • Zelenetz, Andrew D.;
    • Lossos, Izidore S.
    Publication type:
    Article
    35
    36

    Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.

    Published in:
    British Journal of Haematology, 2013, v. 163, n. 4, p. 487, doi. 10.1111/bjh.12570
    By:
    • Ban‐Hoefen, Makiko;
    • Vanderplas, Ann;
    • Crosby‐Thompson, Allison L.;
    • Abel, Gregory A.;
    • Czuczman, Myron S.;
    • Gordon, Leo I.;
    • Kaminski, Mark S.;
    • Kelly, Jennifer;
    • Millenson, Michael;
    • Nademanee, Auayporn P.;
    • Rodriguez, Maria A.;
    • Zelenetz, Andrew D.;
    • Niland, Joyce;
    • LaCasce, Ann S.;
    • Friedberg, Jonathan W.
    Publication type:
    Article
    37

    High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging.

    Published in:
    British Journal of Haematology, 2010, v. 148, n. 6, p. 890, doi. 10.1111/j.1365-2141.2009.08037.x
    By:
    • Moskowitz, Craig H.;
    • Yahalom, Joachim;
    • Zelenetz, Andrew D.;
    • Zhigang Zhang;
    • Filippa, Daniel;
    • Teruya-Feldstein, Julie;
    • Kewalramani, Tarun;
    • Moskowitz, Alison J.;
    • Rice, Robert David;
    • Maragulia, Jocelyn;
    • Vanak, Jill;
    • Trippett, Tanya;
    • Hamlin, Paul;
    • Horowitz, Steven;
    • Noy, Ariela;
    • O'Connor, Owen A.;
    • Portlock, Carol;
    • Straus, David;
    • Nimer, Stephen D.
    Publication type:
    Article
    38

    Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.

    Published in:
    British Journal of Haematology, 2009, v. 146, n. 6, p. 652, doi. 10.1111/j.1365-2141.2009.07775.x
    By:
    • Gerecitano, John;
    • Portlock, Carol;
    • Moskowitz, Craig;
    • Hamlin, Paul;
    • Straus, David;
    • Zelenetz, Andrew D.;
    • Zhigang Zhang;
    • Dumitrescu, Otilia;
    • Sarasohn, Debra;
    • Lin, Dorothy;
    • Pappanicholaou, Jennifer;
    • Cortelli, Barbara M.;
    • Neylon, Ellen;
    • Hamelers, Rachel;
    • Wright, John;
    • O'Connor, Owen A.
    Publication type:
    Article
    39
    40

    Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial

    Published in:
    British Journal of Haematology, 2009, v. 145, n. 1, p. 34, doi. 10.1111/j.1365-2141.2008.07466.x
    By:
    • O'Connor, Owen A.;
    • Moskowitz, Craig;
    • Portlock, Carol;
    • Hamlin, Paul;
    • Straus, David;
    • Dumitrescu, Otilia;
    • Sarasohn, Debra;
    • Gonen, Mithat;
    • Butos, John;
    • Neylon, Ellen;
    • Hamelers, Rachel;
    • Mac-Gregor Cortelli, Barbara;
    • Blumel, Susan;
    • Zelenetz, Andrew D.;
    • Gordon, Leo;
    • Wright, John J.;
    • Vose, Julie;
    • Cooper, Brenda;
    • Winter, Jane
    Publication type:
    Article
    41

    Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.

    Published in:
    British Journal of Haematology, 2007, v. 139, n. 3, p. 425, doi. 10.1111/j.1365-2141.2007.06658.x
    By:
    • Owen A. O'Connor;
    • Hamlin, Paul A.;
    • Portlock, Carol;
    • Moskowitz, Craig H.;
    • Noy, Ariela;
    • Straus, David J.;
    • MacGregor-Cortelli, Barbara;
    • Neylon, Ellen;
    • Sarasohn, Debra;
    • Dumetrescu, Otila;
    • Mould, Diane R.;
    • Fleischer, Martin;
    • Zelenetz, Andrew D.;
    • Sirotnak, Frank;
    • Horwitz, Steven
    Publication type:
    Article
    42
    43
    44
    45
    46
    47
    48
    49
    50

    Zandelisib and B-Cell Lymphomas.

    Published in:
    Clinical Advances in Hematology & Oncology, 2023, v. 21, n. 3, p. 117
    By:
    • Zelenetz, Andrew D.
    Publication type:
    Article